AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vir Biotechnology, Inc. Director's Dealing 2023

Mar 31, 2023

32538_dirs_2023-03-31_854cf5ba-a1e7-4625-8e73-457685392195.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2023-03-30

Reporting Person: HANLY ANN M. (Chief Technology Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-30	Common Stock	S	2627	$22.77	Disposed	114576	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	11.52	Indirect

Footnotes

F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.

F2: The shares are beneficially owned by the reporting person's spouse, for the benefit of a minor child.